7-chloro-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one | 1020039-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-chloro-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
• 英文别名: 7-chloro-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one；7-chloro-2H-[1,2,4]triazolo[4,3-a]pyridin-3-one
• CAS: 1020039-12-6
• 化学式: C₆H₄ClN₃O
• mdl: MFCD09994118
• 分子量: 169.57
• InChiKey: RJGCGYRBLODQEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(hydroxymethyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 、 7-chloro-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-((7-chloro-3-oxo-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
  参考文献：
  名称：

  The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties

  摘要：

  The sodium glucose co-transporter 2 (SGLT2) has received considerable attention in recent years as a target for the treatment of type 2 diabetes mellitus. This report describes the design, synthesis and structure-activity relationship (SAR) of C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties as novel SGLT2 inhibitors. Compounds 5p and 33b demonstrated high potency in inhibiting SGLT2 and high selectivity against SGLT1. The in vitro ADMET properties of these compounds will also be discussed. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.04.036

文献信息

• [EN] 15-PGDH INHIBITORS<br/>[FR] INHIBITEURS DE 15-PGDH
  申请人：KYORIN SEIYAKU KK

  公开号：WO2020160151A1

  公开（公告）日：2020-08-06

  A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.

  具有以下式之一的化合物（1），（2），（3）和（4）或其药理学上可接受的盐。
• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020097609A1

  公开（公告）日：2020-05-14

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的失调的方法。这些化合物具有Formula（X）的结构或其在药学上可接受的异构体，消旋体，水合物，溶剂合物，同位素或盐，其中R1，R2，R3，R4，R9，R10，R11和R12，Q5，Q6，Q7和Q8如本文所定义。
• [EN] D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'ACTIVITÉ DE D-AMINO ACIDE OXYDASE
  申请人：RICHTER GEDEON NYRT

  公开号：WO2019043635A1

  公开（公告）日：2019-03-07

  Compounds of formula (I), wherein R1 through R3 are as defined in the claims, or pharmaceutically acceptable esters, salts, hydrates or solvates thereof, useful as DAAO inhibitors as well as pharmaceutical compositions containing them and their use as modulators of DAAO activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject are provided.

  式(I)的化合物，其中R1至R3如权利要求中所定义，或其药用可接受的酯、盐、水合物或溶剂化合物，可用作DAAO抑制剂，以及含有它们的药物组合物以及它们作为DAAO活性调节剂、D-丝氨酸水平、D-丝氨酸氧化产物和NMDA受体活性在哺乳动物主体的神经系统中的使用。
• The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
  作者：Cheng Guo、Min Hu、Russell J. DeOrazio、Alexander Usyatinsky、Kevin Fitzpatrick、Zhenjun Zhang、Jun-Ho Maeng、Douglas B. Kitchen、Susan Tom、Michele Luche、Yuri Khmelnitsky、Andrew J. Mhyre、Peter R. Guzzo、Shuang Liu

  DOI：10.1016/j.bmc.2014.04.036

  日期：2014.7

  The sodium glucose co-transporter 2 (SGLT2) has received considerable attention in recent years as a target for the treatment of type 2 diabetes mellitus. This report describes the design, synthesis and structure-activity relationship (SAR) of C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties as novel SGLT2 inhibitors. Compounds 5p and 33b demonstrated high potency in inhibiting SGLT2 and high selectivity against SGLT1. The in vitro ADMET properties of these compounds will also be discussed. (C) 2014 Elsevier Ltd. All rights reserved.